Roquefort Therapeutics PLC (LSE:ROC) has announced the acquisition of Coiled Therapeutics, Inc., a clinical-stage oncology firm, through a reverse takeover valued at £30 million in shares. This deal marks a pivotal shift for Roquefort, transitioning it into a clinical-stage biotech player with a stronger portfolio of advanced assets. Among these is AO-252, a cancer therapy currently in Phase I trials that holds considerable promise.
As part of the transaction, A2A Pharmaceuticals has committed significant funding to back Roquefort’s growth and pipeline expansion. The acquisition also establishes a strategic partnership with A2A, giving Roquefort access to its SCULPT™ drug discovery platform, which is expected to provide further opportunities for innovation. Management views the deal as a major step in enhancing shareholder value and strengthening the company’s market position.
About Roquefort Therapeutics PLC
Roquefort Therapeutics PLC is a London-listed biotechnology company focused on advancing from pre-clinical research to clinical-stage development. Its work centers on oncology drug discovery and development, incorporating machine learning technologies to improve treatment outcomes and accelerate progress in the field.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply